MANNKIND CORP
MNKD evidence brief
What we can confirm
- BioSniper Score:
- 4.0 / 10
- Market Cap:
- $1.21B
- Lead Asset:
- afrezza (Phase 4)
What it means
What to watch
Prepared research question
What matters most for MNKD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MNKD
MANNKIND CORP (MNKD) is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases, with commercial products including Afrezza (inhaled insulin) and FUROSCIX, and a pipeline of inhaled therapies for pulmonary fibrosis and nontuberculous mycobacterial infection.
Key risk: High debt burden
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 6 clinical trials · 1 catalyst · 1 FDA decision for MANNKIND CORP.
MANNKIND CORP (MNKD) is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases, with commercial products including Afrezza (inhaled insulin) and FUROSCIX, and a pipeline of inhaled therapies for pulmonary fibrosis and nontuberculous mycobacterial infection.
- Cash & equivalents of $52.9M as of 2026-06-30 [sec].
- Total revenue of $109.4M and net income of -$19.0M as of 2026-06-30 [sec].
- Shareholders' equity of -$67.2M and total debt of $325.0M as of 2026-06-30 [sec].
- Commercial products include Afrezza (inhaled insulin) and FUROSCIX (for fluid overload) [sec · filed 2026-04-07].
- Pipeline includes MNKD-201 (nintedanib DPI for IPF) in Phase 1b/2 and MNKD-1501 (ralinepag DPI) in collaboration with UT [sec · filed 2026-04-07].
What works
- Revenue growth trajectory: Q1 2026 total revenues of $90.2M, +15% vs. Q1 2025 [news · published 2026-05-06].
- Multiple near-term regulatory catalysts: Afrezza pediatric PDUFA date May 29, 2026 and FUROSCIX ReadyFlow Autoinjector PDUFA date July 26, 2026 [news · published 2026-05-06].
- Pipeline expansion through collaboration: In August 2025, announced expansion to formulate MNKD-1501 with UT conducting preclinical and clinical development [sec · filed 2026-04-07].
- Phase 3 trial (ICoN-1) for MNKD-101 (clofazimine inhalation suspension for NTM) achieved interim enrollment target ahead of schedule [news · published 2025-11-05].
What to weigh
- Negative net income of -$19.0M as of 2026-06-30 [sec].
- Negative shareholders' equity of -$67.2M as of 2026-06-30 [sec].
- High total debt of $325.0M as of 2026-06-30 [sec].
- Afrezza faces competition from rapid-acting insulin analogs marketed by Eli Lilly, Sanofi, and Novo Nordisk, as well as GLP-1 analog injection products [pipeline].
From the filings
Quoted directly from source documents.
Afrezza pediatric PDUFA date
“Afrezza® pediatric indication PDUFA date May 29, 2026”
News · May 6, 2026
Catalyst timeline
- 2042-02-03 · Patent_Expiry · TREPROSTINIL — Patent expiry for NDA214324; may affect market exclusivity for treprostinil products.
Risks & what to watch (4)›
Key risks
- High debt burden — Total debt of $325.0M as of 2026-06-30 [sec].
- Negative equity — Shareholders' equity of -$67.2M as of 2026-06-30 [sec].
- Competitive pressure on Afrezza — Afrezza competes with rapid-acting insulin analogs from Eli Lilly, Sanofi, Novo Nordisk, and GLP-1 analogs [pipeline].
- Patent expiry risk — Patent expiry for TREPROSTINIL on 2042-02-03 [catalyst].
What to watch
- Afrezza pediatric PDUFA date May 29, 2026 [news · published 2026-05-06].
- FUROSCIX ReadyFlow Autoinjector PDUFA date July 26, 2026 [news · published 2026-05-06].
- MNKD-201 Phase 2 INFLO-2 trial first patient enrollment expected Q2 2026 [news · published 2026-05-06].
- Patent expiry for TREPROSTINIL on 2042-02-03 [catalyst].
Sources: Catalysts · News · Pipeline · SEC filings · SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run MANNKIND CORP through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MANNKIND CORP facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$19M
Lead: Approved
2 candidates
1 upcoming, next in ~5591d
0 buys · 5 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 1, 2026- % of float
- 9.7%
- Days to cover
- 5.4
- Shares short
- 29,576,907
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MNKD short interestGovernance
Frequently asked questions
What is the AI investment thesis for MANNKIND CORP?
MANNKIND CORP (MNKD) is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases, with commercial products including Afrezza (inhaled insulin) and FUROSCIX, and a pipeline of inhaled therapies for pulmonary fibrosis and nontuberculous mycobacterial infection.
What is MANNKIND CORP's lead drug candidate?
MANNKIND CORP's most advanced tracked candidate is afrezza (Phase 4) for Diabetes Mellitus, Type 1; Type 1 Diabetes.
What is MANNKIND CORP's next catalyst?
MANNKIND CORP's next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA214324" — expected February 3, 2042.
Who is the CEO of MANNKIND CORP?
Dr. Michael E. Castagna Pharm.D. is the chief executive officer of MANNKIND CORP (MNKD).
Where is MANNKIND CORP headquartered?
MANNKIND CORP (MNKD) is headquartered in Danbury, CT, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.